In a clinical trial, the experimental drug daraxonrasib stopped tumor growth in 90.2% of patients with advanced pancreatic cancer, according to findings presented on Friday.
* Daraxonrasib, marketed as Rasonque, resulted in tumor shrinkage or disappearance in 60.7% of the 61 trial participants.
* The drug, which targets KRAS and other RAS proteins, achieved undetectable tumor status in 8.2% of patients.
* Researchers observed that approximately 77% of patients remained alive one year after starting the treatment.
“This represents a potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer,” Dr. Wungki Park, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York, said.
The findings, presented at an international cancer research conference in Barcelona, Spain, offer a potential new path for a disease that the American Cancer Society estimates will see 67,530 new diagnoses in 2026, while approximately 52,740 Americans will die from the disease. Pancreatic cancer remains the nation’s third-leading cause of cancer deaths.
According to the National Cancer Institute, the overall five-year relative survival rate is just 13.7%, and for patients whose cancer has already spread to distant organs, survival prospects are considerably worse. Pancreatic cancer is especially dangerous because early symptoms are frequently absent or vague.
Daraxonrasib functions by blocking proteins that act as molecular switches for cell growth. When these proteins mutate, they can remain permanently activated, driving the uncontrolled expansion of cancer cells. The median period before cancer worsened for patients in the trial was 12.8 months.
Although European regulators have already authorized the medication, this recent research investigates its application in conjunction with chemotherapy as a primary treatment, a strategy that has not yet been validated by these specific results.
Researchers are investigating other promising treatments, such as zoldonrasib, which is designed to block a specific KRAS mutation known as G12D often found in pancreatic tumors. Another avenue being explored involves training the immune system to recognize proteins associated with pancreatic tumors to potentially prevent recurrence. Despite the excitement, researchers caution that the 90% figure represents disease control, not a cure.
Oncology approvals keep changing. The Food and Drug Administration authorized giredestrant (Wilserdly, Genentech, Inc.)—an oral estrogen receptor antagonist—paired with everolimus on November 16, 2026, to treat adults diagnosed with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. On November 13, 2026, the FDA approved durvalumab (Imfinzi, AstraZeneca) in combination with enfortumab vedotin-ejfv as neoadjuvant treatment for adult patients with muscle invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. On November 10, 2026, the FDA approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor for which surgical resection may cause worsening functional limitation or severe morbidity.
The Food and Drug Administration provided accelerated approval for amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) on November 5, 2026, for adult patients suffering from recurrent or metastatic head and neck squamous cell carcinoma who saw their condition worsen following treatment with an anti-PD-(L)1 antibody and platinum-based chemotherapy.
In addition, the FDA authorized the use of atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) alongside a fluoropyrimidine and oxaliplatin to provide adjuvant therapy for pediatric and adult patients 12 years of age and older who weigh at least 40 kg and have Stage III dMMR colon cancer.
Memorial Sloan Kettering Cancer Center, one of 72 National Cancer Institute–designated Comprehensive Cancer Centers, maintains a long-standing reputation for integrating patient care with advanced clinical and laboratory research. This model of excellence began in 1927 when the institution created the first fellowship training program in the United States, establishing a framework for physician-led innovation that persists today.
The institution’s commitment to scientific discovery dates back to 1945, when the Sloan-Kettering Institute for Cancer Research was established to apply industrial research techniques to oncology. By fostering historic collaborations between clinicians and laboratory scientists, the center has consistently prioritized the rapid translation of experimental findings into clinical practice, a legacy that informs the work of modern specialists currently evaluating breakthrough therapies for complex diseases like pancreatic cancer.
New targeted therapies demonstrate clinical progress
Beyond pancreatic research, a new class of ultra-targeted anticancer therapy known as antibody-drug conjugates (ADCs) has garnered significant attention at the American Society of Clinical Oncology congress. According to Futura-Sciences, these treatments function like a guided missile to deliver chemotherapy directly into tumor cells, successfully shrinking tumors in a third of women at higher doses in recent trials.